Literature DB >> 35183435

Bacteriophage therapy as a treatment option for complex cardiovascular implant infection: The German Heart Center Berlin experience.

Tamta Tkhilaishvili1, Evgenij Potapov2, Christoph Starck2, Johanna Mulzer3, Volkmar Falk4, Andrej Trampuz5, Felix Schoenrath2.   

Abstract

Conventional antimicrobials have low or no activity against multidrug-resistant or chronic implant-associated infections. Lytic bacteriophages can rapidly and selectively kill bacteria, and can be combined with antibiotics. However, clinical experience of bacteriophage therapy in patients with cardiovascular infections is limited. We documented the outcome and safety of intravenous and local adjunctive bacteriophage therapy, to treat chronic relapsing cardiovascular implant infections at our institution.
Copyright © 2022 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  alternative therapy; bacteriophage therapy; biofilm infections; cardiovascular implant infections; multidrug resistant infections

Mesh:

Substances:

Year:  2022        PMID: 35183435     DOI: 10.1016/j.healun.2022.01.018

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  1 in total

1.  Bacteriophage-Enriched Galenic for Intrapericardial Ventricular Assist Device Infection.

Authors:  Sebastian V Rojas; Simon Junghans; Henrik Fox; Kanstantsin Lazouski; Rene Schramm; Michiel Morshuis; Jan F Gummert; Justus Gross
Journal:  Antibiotics (Basel)       Date:  2022-04-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.